Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07004335 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

StatusNot Yet Recruiting
PhasePhase 4
Started2025-07-01
View on ClinicalTrials.gov ↗
Several studies have shown that the combination of Iparomlimab, Tuvonralimab, and Bevacizumab exhibits potent anti-tumor activity and favorable safety in various solid tumors, including liver cancer. However, the efficacy and safety of this regimen in melanoma patients with acquired resistance to immunotherapy remain unexplored and require further validation. This study aims to evaluate the efficacy and safety of the Iparomlimab, Tuvonralimab, and Bevacizumab combination in patients with immune-resistant melanoma. Furthermore, it will analyze and compare treatment responses among different melanoma subtypes to identify optimal treatment strategies for clinical practice.
Trial Details
NCT Number NCT07004335
Lead Sponsor Hebei Medical University Fourth Hospital
Collaborators: Qilu Pharmaceutical Co., Ltd.
Conditions PD-(L)1, CTLA-4, Advanced Melanoma, Iparomlimab, Tuvonralimab, Bevacizumab
Enrollment 40 participants
Start Date 2025-07-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-04